ENTPD1 and acute myeloid leukemia: Next, we analyzed the therapeutic potential of blocking TIGIT and the purinergic signaling via anti-CD39 blockade or adenosine A2A receptor (A2AR) antagonism on natural killer cells to restore the function of exhausted NK cells and improve their cytotoxic activity against AML cells.